Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-08-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes shareholder information and notes on company control and important matters. The document is about 2814 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement or a certification, but a summary report with financial figures and company information for the half-year period. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2023
2023-08-28 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 年半年度报告全文" which translates to the "2023 Semi-Annual Report Full Text" of Shenzhen Neptunus Bioengineering Co., Ltd. It contains detailed financial data, management discussion and analysis, company overview, business segments, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2023 to June 30, 2023, which is a half-year period. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for Shenzhen Haier Bioengineering Co., Ltd. for the half-year period of 2023. It includes financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances for various related parties and subsidiaries. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. It contains detailed financial data and analysis for a period shorter than a full fiscal year (half-year). There is no indication that this is an annual report, audit report, or earnings release. The content aligns with an Interim / Quarterly Report, which covers comprehensive financial data for a shorter period than a full fiscal year. H1 2023
2023-08-28 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' special statement and opinion regarding the company's 2023 half-year external guarantees and fund occupation situation. It references regulatory guidelines and compliance with the China Securities Regulatory Commission rules. The content is a formal opinion on specific governance and financial matters for a half-year period ending June 30, 2023. The document length is short (781 characters) and it does not contain full financial statements or detailed financial data, but rather an independent directors' review and opinion on a specific issue related to the interim period. This fits best under Board/Management Information (MANG) as it relates to board-level oversight and opinions on company matters, rather than a full interim report or audit report. It is not a full Annual Report, Interim Report, or Audit Report, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is MANG with high confidence.
2023-08-28 Chinese
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of planning a major matter, specifically a major asset restructuring and mixed ownership reform. It mentions that no formal agreement has been signed yet and that the company will continue to disclose information as required by law. The document references regulatory guidelines for major asset restructuring and states that monthly progress updates are published. The document is short (1108 characters) and serves as a progress update announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis but is an update on a capital restructuring process. Therefore, it fits best under Capital/Financing Update (CAP).
2023-08-28 Chinese
2023年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2023 年半年度财务报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2023 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2023. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for the period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.